for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Merck’s Keytruda Approved In China For Esophageal Squamous Cell Carcinoma

June 22 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA (PEMBROLIZUMAB) APPROVED IN CHINA FOR SECOND-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

* MERCK - KEYTRUDA IS NOW APPROVED ACROSS FIVE INDICATIONS FOR THREE DIFFERENT TYPES OF CANCER IN CHINA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up